BTIG Starts Lyra Therapeutics (LYRA) at Buy

May 26, 2020 7:39 AM EDT
Get Alerts LYRA Hot Sheet
Price: $8.66 -4.31%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 15 | Down: 13 | New: 24
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

BTIG analyst Robert Hazlett initiates coverage on Lyra Therapeutics (NASDAQ: LYRA) with a Buy rating and a price target of $28.00.

The analyst commented, "Lyra Therapeutics is developing a novel drug delivery platform for ear, nose and throat (ENT) disease. Its technology platform called XTreo is a polymer-based system that is able to deliver a consistent, continuous dose of a therapeutic over an extended period of time to nasal mucosal tissue. Lyra’s lead program, LYR-210, has a tubular mesh configuration with elastic properties that is designed to promote comfort as well as retention in the mucosal tissue of the sinus. LYR-210 is able to deliver a continuous dose of the well-characterized steroid mometasone over 6 months to treat patients with chronic rhinosinusitis (CRS) who have not had sinus surgery. CRS is a condition that is characterized by inflammation of the paranasal sinuses that affects over 13 million in the US. Nearly 8 million seek treatment for CRS, and LYR-210 is being developed for the nearly 50% who fail existing medical management of the condition. LYR-220, a larger version of LYR-210, is being developed for patients who have previously undergone surgical intervention for their CRS, who continue to experience symptoms. With significant potential for the successful development of both LYR-210 and LYR-220 in CRS patients both with and without polyps, we initiate coverage of Lyra with a Buy rating and a $28 price target."

For an analyst ratings summary and ratings history on Lyra Therapeutics click here. For more ratings news on Lyra Therapeutics click here.

Shares of Lyra Therapeutics closed at $14.43 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities